American Society of Clinical Oncology Policy Statement on Clinical Pathways in Oncology
- 1 March 2016
- journal article
- asco special-articles
- Published by American Society of Clinical Oncology (ASCO) in Journal of Oncology Practice
- Vol. 12 (3), 261-266
- https://doi.org/10.1200/jop.2015.009134
Abstract
The use of clinical pathways in oncology care is increasingly important to patients and oncology providers as a tool for enhancing both quality and value. However, with increasing adoption of pathways into oncology practice, concerns have been raised by ASCO members and other stakeholders. These include the process being used for pathway development, the administrative burdens on oncology practices of reporting on pathway adherence, and understanding the true impact of pathway use on patient health outcomes. To address these concerns, ASCO’s Board of Directors established a Task Force on Clinical Pathways, charged with articulating a set of recommendations to improve the development of oncology pathways and processes, allowing the demonstration of pathway concordance in a manner that promotes evidence-based, high-value care respecting input from patients, payers, and providers. These recommendations have been approved and adopted by ASCO’s Board of Directors on August 12, 2015, and are presented herein.Keywords
This publication has 5 references indexed in Scilit:
- The State of Cancer Care in America, 2015: A Report by the American Society of Clinical OncologyJournal of Oncology Practice, 2015
- Equity in cancer care: pathways, protocols, and guidelines.Journal of the National Comprehensive Cancer Network, 2012
- Pathways, Outcomes, and Costs in Colon Cancer: Retrospective Evaluations in Two Distinct DatabasesJournal of Oncology Practice, 2011
- Strategic Use of Clinical PathwaysJournal of Oncology Practice, 2011
- Cost Effectiveness of Evidence-Based Treatment Guidelines for the Treatment of Non–Small-Cell Lung Cancer in the Community SettingJournal of Oncology Practice, 2010